Dr. Andree Blaukat has been Tesselate Bio’s CEO since Nov. 2022.  Before, he has served as SVP and Global Head Oncology Research at Merck KGaA, Darmstadt, Germany.  He was core member of the committee overseeing all discovery projects across therapeutic areas, the Development Unit and the Franchise Leadership Teams with responsibility for clinical development and commercialization of oncology products.  Andree has served in various leadership roles in Oncology R&D during his 20-year tenure at Merck, focusing on drug discovery, translational research and early clinical development.  Under his leadership, several drug candidates were discovered and developed, key strategic collaborations and licensing deals were executed and the focus areas of the company, precision oncology, DNA damage response and antibody-drug conjugates were established.

Prior to joining Merck, Andree was a Group Leader and lecturer for pharmacology and toxicology at the University of Heidelberg and Postdoctoral Fellow at the Ludwig Institute for Cancer Research in Uppsala, Sweden.  He obtained his PhD in biochemistry from the Universities of Mainz and Darmstadt in 1997.  Andree was co-organizer of the “Perspective Lectures in Oncology” at the University of Frankfurt initiated in 2010.  He has published >60 scientific manuscripts and book chapters as well as >30 patents.